C82.6
Cutaneous follicle center lymphoma
Clinical Classification Guidelines
Medical Intelligence & Overview
Cutaneous follicle center lymphoma (C-FCL) is a rare type of non-Hodgkin lymphoma that primarily affects the skin. It originates from the cells within the follicle centers of lymph nodes, which play a role in immune responses. This lymphoma is classified as a low-grade, indolent lymphoma, meaning it tends to grow slowly and may not cause immediate symptoms. Recognizing and understanding C-FCL is important for proper diagnosis and management, although it is generally associated with a favorable prognosis compared to more aggressive lymphomas.
Causes & Symptoms
Clinical Causes: The exact cause of cutaneous follicle center lymphoma is unknown. It involves the abnormal proliferation of B-cells, a type of white blood cell involved in immune response. Genetic mutations within B-cells may contribute to the development of the disease. Environmental factors and immune system dysregulation may play a role, but specific triggers are not well established.
Key Symptoms: Slow-growing, painless skin nodules or plaques Lesions are often encountered on the head, neck, or upper trunk Lesions may be skin-colored, reddish, or bluish and can vary in size In some cases, multiple lesions may appear over time Symptoms are usually limited to the skin; systemic symptoms like fever or weight loss are uncommon
Diagnostic & Treatment
Diagnosis Path: Diagnosing cutaneous follicle center lymphoma involves several steps:
Treatment Protocols: The management of cutaneous follicle center lymphoma depends on several factors, including the extent of skin involvement and whether the disease has spread beyond the skin. Common treatment options include:
Clinical Advice & FAQs
Billing Guidance
Is C82.6 a billable ICD-10 code?
Yes, C82.6 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C82.6?
Clinical documentation must specify the nature of Cutaneous follicle center lymphoma and any associated comorbidities for accurate reporting.
Cite this Clinical Reference